(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 February 2004 (05.02.2004)

PCT

(10) International Publication Number
WO 2004/011436 A1

(51) International Patent Classification[7]: C07D 215/22, A61K 31/47, A61P 31/06, C07D 409/06, 215/36, 405/06, 401/06, 405/04, 215/48, 409/04, 401/12, 471/04 // (C07D 471/04, 235:00, 221:00)

(21) International Application Number:
PCT/EP2003/050322

(22) International Filing Date: 18 July 2003 (18.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/398,711 25 July 2002 (25.07.2002) US

(71) Applicant *(for all designated States except US)*: **JANSSEN PHARMACEUTICA N.V.** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(71) Applicant and
(72) Inventor: **GUILLEMONT, Jérôme, Emile, Georges** [FR/FR]; C/O Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **VAN GESTEL, Jozef, Frans, Elisabetha** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **VENET, Marc, Gaston** [FR/FR]; 10, Square de Bourgogne, F-76240 Le Mesnil-Esnard (FR). **POIGNET, Hervé, Jean, Joseph** [FR/FR]; C/O Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR). **DECRANE, Laurence, Françoise, Bernadette** [FR/FR]; C/O Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR). **VERNIER, Daniel, F., J.** [FR/FR]; C/O Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR).


(74) Common Representative: **JANSSEN PHARMACEUTICA N.V.**; Turnhoutseweg 30, B-2340 Beerse (BE).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

[Continued on next page]

(54) Title: QUINOLINE DERIVATIVES AND THEIR USE AS MYCOBACTERIAL INHIBITORS





(57) Abstract: The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or the general Formula (Ib), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the *N*-oxide forms thereof. The claimed compounds are useful for the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as *Mycobacterium tuberculosis, M. bovis, M. avium and M. marinum.* In particular, compounds are claimed in which, independently from each other, R^1 is bromo, p=1, R^2 is alkyloxy, R^3 is optionally substituted naphthyl or phenyl, q=1, R^4 and R^5 each independently are hydrogen, methyl or ethyl, R^6 is hydrogen, r is equal to 0 or 1 and R^7 is hydrogen. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of mycobacterial diseases and a process for preparing the claimed compounds.

WO 2004/011436 A1

SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*
— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.